SCHEMBL5540547

SCHEMBL5540547

CCCCCc1ccc2nc(O)sc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 9/20 0.48
SENP8 Q96LD8 9/20 0.48
SENP7 Q9BQF6 9/20 0.48
SENP6 Q9GZR1 9/20 0.48
PCSK9 Q8NBP7 1/20 0.48
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ESR1 P03372 2/20 0.45
ADRA2A P08913 2/20 0.45
ADORA3 P0DMS8 2/20 0.45
TACR2 P21452 2/20 0.45
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 2/20 0.45
SLC6A3 Q01959 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
SHBG P04278 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542735 0.95 CASP3 (0.52) CASP3SENP8SENP7SENP6PCSK9
SCHEMBL5545588 0.89 RAB9A (0.49) CASP3SENP8SENP7SENP6PCSK9
SCHEMBL5946928 0.83 CASP3 (0.46) CASP3SENP8SENP7SENP6PCSK9
SCHEMBL5538757 0.83 HSD17B10 (0.46) CASP3SENP8SENP7SENP6PCSK9
SCHEMBL19997568 0.82 RAB9A (0.65) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL5540542 0.82 CASP3 (0.48) CASP3SENP8SENP7SENP6PCSK9
SCHEMBL22926235 0.82 SMN1; SMN2 (0.49) CASP3SENP8SENP7SENP6PCSK9
SCHEMBL8656868 0.82 RAB9A (0.69) CASP3SENP8SENP7SENP6NPC1
SCHEMBL2443034 0.82 CASP3 (0.51) CASP3SENP8SENP7SENP6PCSK9
SCHEMBL8554888 0.81 MAPT (0.56) NPC1RAB9ASMN1; SMN2ESR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CASP3 1021/4885SENP8 4471/4885SENP7 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.